Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 5, 1999, Pages 483-490

  Scheffler, Michael R ^b   Colburn, Wayne ^b   Kook, Karin A ^b   Thomas, Steve D ^a  

^a CELGENE CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; THALIDOMIDE;

ARTICLE; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; LEPROSTATIC AGENTS; NORETHINDRONE; REFERENCE VALUES; THALIDOMIDE;

EID: 2342534020     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70067-6     Document Type: Article

References (27)

1. 1. Mellin GW, Katzenstein M. The saga of thalidomide (concluded). Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962;267:1128-34.
2. 2. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998;17:231-42.
3. 3. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
4. 4. Alexander LN, Wilcox CM. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997;13: 301-4.
5. 5. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V M, Arroyo-Figueroa H, Pasquetti A, Calva JJ, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
6. 6. Kaplan G. Thalidomide promotes weight gain and increase in fat-free mass in HIV-associated wasting. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998; abstract 476.
7. 7. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980;269:275-80.
8. 8. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
9. 9. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-23.
10. 10. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Mechan JW, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:523-31.
11. 11. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme MLE, et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980;21:135-43.
12. 12. Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf 1993;9:21-37.
13. 13. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-6.
14. 14. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. In: Snow R, Hall P, editors. Steroid contraceptives and women's response. New York: Plenum Press; 1994.
15. 15. Tsambaos D, Bolsen K, Georgiou S, Monastirli A, Goerz G. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. Arch Dermatol Res 1994;286:347-9.
16. 16. Wiener H, Krivanek P, Tuisl E, Kolassa N. Induction of drug metabolism in the rat by taglutimide, a sedative-hypnotic glutarimide derivative. Eur J Drug Metab Pharmacokinet 1980;5:93-7.
17. 17. Tektagen Inc. High performance liquid chromatography assay for the determination of the quantity of thalidomide in human plasma. Malvern (PA): Tektagen; Document CTM-2070.
18. 18. PPD Pharmaco Inc. GC/MS analysis of 17α-ethinyl estradiol and norethindrone in human serum. Richmond (VA): PPD Pharmaco; April 1997.
19. 19. Chen TL, Vogelsang GB, Petty BG, Brundrett RB, Noe DA, Santos GW, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17:402-5.
20. 20. SAS Institute. SAS/STAT user's guide; version 6. Fourth ed; vol 1. Cary (NC): SAS Institute; 1989.
21. 21. SAS Institute. SAS/STAT user's guide; version 6. Fourth ed; vol 2. Cary (NC): SAS Institute; 1989.
22. 22. SAS Institute. SAS procedures guide; version 6. Third ed. Cary (NC): SAS Institute; 1990.
23. 23. Schumacher H, Blake DA, Gillette JR. Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968;160:201-11.
24. 24. Ball SE, Forrester LM, Wolf CR, Back DJ. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Relative activities of rat and human liver enzymes. Biochem J 1990;267:221-6.
25. 25. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990;163:2159-63.
26. 26. D'Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986;20:353-62.
27. 27. Teo S, Sabourin A, Kook K, Thomas S. Eur J Drug Mebab Pharmacokinet [in press].